C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. The company has a suite of proprietary technologies across the drug discovery process, including Taxonomy 3, a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules; and MolPlex. Its product pipeline comprises Oral Orexin-1, an antagonist for the treatment of addiction; Oral GPR142 and GLP-1, an agonist for the treatment of type 2 diabetes; Oral Nrf-2 activators and IL-17 inhibitors for the treatment of inflammatory disorders; and various products for the treatment of oncology. The company has collaboration agreement with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and a discovery partnership with Horizon Discovery Group plc to develop synthetic lethality targets in oncology. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-161-2355085
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£7.06 million
Profitability
Miscellaneous
Employees47
Next Earnings DateN/A
OptionableNot Optionable
C4X Discovery (LON:C4XD) Frequently Asked Questions
What is C4X Discovery's stock symbol?
C4X Discovery trades on the London Stock Exchange (LON) under the ticker symbol "C4XD."
How were C4X Discovery's earnings last quarter?
C4X Discovery Holdings PLC (LON:C4XD) released its earnings results on Tuesday, April, 30th. The company reported ($9.38) earnings per share for the quarter, beating the Zacks' consensus estimate of ($11.00) by $1.62. View C4X Discovery's Earnings History.
Has C4X Discovery been receiving favorable news coverage?
Headlines about C4XD stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. C4X Discovery earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for C4X Discovery.
Who are some of C4X Discovery's key competitors?
Some companies that are related to C4X Discovery include Acasti Pharma (ACST), Zelda Therapeutics (ZLD), Protalix Biotherapeutics (PLX), ReNeuron Group (RENE), Immunoprecise Antibodies (IPA), Actinium Pharmaceuticals (ATNM), OptiBiotix Health (OPTI), Armata Pharmaceuticals (ARMP), Actinium Pharmaceuticals (ATNM), 4d Pharma (DDDD), Emerald Health Therapeutics (EMH), Covalon Technologies (COV), AquaBounty Technologies (AQB), Kazia Therapeutics (KZA) and Race Oncology (RAC).
What other stocks do shareholders of C4X Discovery own?
Who are C4X Discovery's key executives?
C4X Discovery's management team includes the folowing people:
- Dr. Clive James Dix, CEO & Director (Age 64)
- Mr. Bradley Richard Hoy, CFO & Director (Age 56)
- Dr. Justian Craig Fox, Chief Scientific Officer & Director (Age 44)
- Ms. Bhavna Hunjan, Head of Corp. Strategy & Devel.
- Mr. Mark James Sullivan, Company Sec.
How do I buy shares of C4X Discovery?
Shares of C4XD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is C4X Discovery's stock price today?
One share of C4XD stock can currently be purchased for approximately GBX 11.75.
How big of a company is C4X Discovery?
What is C4X Discovery's official website?
How can I contact C4X Discovery?
C4X Discovery's mailing address is 53 Portland Street, MANCHESTER, M1 3LD, United Kingdom. The company can be reached via phone at +44-161-2355085.
MarketBeat Community Rating for C4X Discovery (LON C4XD)
MarketBeat's community ratings are surveys of what our community members think about C4X Discovery and other stocks. Vote "Outperform" if you believe C4XD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe C4XD will underperform the S&P 500 over the long term. You may vote once every thirty days.
